Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07221877 · ClinicalTrials.gov registry record · Phase 4
A Study to Evaluate the Effect of KarXT on Urological Safety
A Phase 4 study of Schizophrenia, sponsored by Bristol-Myers Squibb.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
- 14
- Study locations
NCT07221877: Recruiting Phase 4 study of Schizophrenia, sponsored by Bristol-Myers Squibb.
NCT07221877 is a Phase 4 study of Schizophrenia that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 60 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (73% lower). The trial reports 14 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07221877, a Phase 4 study of Schizophrenia, is actively recruiting participants, sponsored by Bristol-Myers Squibb.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
- 14
- Study locations
Study Summary
The purpose of this study is to characterize the effect of KarXT on voiding dynamics and urological safety in participants with DSM-5 schizophrenia.
Conditions Studied
Interventions
- DRUG Xanomeline/trospium chloride
Study Locations (14)
California
- Local Institution - 0007 - Bellflower
- Local Institution - 0009 - Culver City
- CenExel CNS - Garden Grove - Garden Grove
- Local Institution - 0016 - Orange
Florida
- Local Institution - 0003 - Miami
- Local Institution - 0004 - Stuart
Illinois
- Uptown Research Institute - Chicago
- Local Institution - 0010 - Chicago
Texas
- Local Institution - 0001 - Austin
- InSite Clinical Research - DeSoto
Arkansas
- Local Institution - 0017 - Little Rock
Nevada
- Local Institution - 0013 - Las Vegas
New Jersey
- Hassman Research Institute Marlton Site - Marlton
Pennsylvania
- Adams Clinical Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2026-01-20 |
| Est. Completion | 2027-12-30 |
| Phase | Phase 4 |
What NCT07221877 shows while recruiting
NCT07221877 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (73% lower).
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which Xanomeline/trospium chloride is the first listed.
NCT07221877 lists 14 locations in 8 states (California, Florida, Illinois).
Frequently Asked Questions
What is clinical trial NCT07221877 about?
NCT07221877 is a clinical study titled "A Study to Evaluate the Effect of KarXT on Urological Safety". The purpose of this study is to characterize the effect of KarXT on voiding dynamics and urological safety in participants with DSM-5 schizophrenia.
What is the current status of trial NCT07221877?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2026-01-20. Estimated completion is 2027-12-30.
What conditions does trial NCT07221877 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT07221877?
The interventions under investigation include: Xanomeline/trospium chloride (DRUG).
Who is sponsoring clinical trial NCT07221877?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07221877 being conducted?
This trial has 14 study locations across Arkansas, California, Florida, Illinois, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07221877's enrollment target sits among peer trials
60 188th of 315 higher than 119 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia
RECRUITING · Phase 4
-
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
RECRUITING · Phase 4
-
CLOZAPINE Response in Biotype-1
RECRUITING · Phase 4
-
Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates
RECRUITING · Phase 4
-
Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial
RECRUITING · Phase 4
-
Anti-Inflammatory Challenge in Schizophrenia
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI